News from novartis pharmaceuticals corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 08, 2019, 07:15 ET Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept

Novartis today announced that the U.S. Food and Drug Administration (FDA) approved BEOVU® (brolucizumab-dbll) injection, also known as RTH258, for...


Oct 02, 2019, 01:20 ET Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum

Novartis, a leader in rheumatology and immuno-dermatology, today announced additional positive data from the PREVENT trial, evaluating the efficacy...


Sep 02, 2019, 02:32 ET Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings

Novartis announced today results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of...


Jul 22, 2019, 07:30 ET Novartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch My Home In Sight, A Program Empowering People With Wet AMD To Live More Independently At Home

Novartis is teaming up with celebrity interior designer Nate Berkus to launch My Home in Sight, a program that aims to raise awareness of the daily...


Jul 16, 2019, 01:23 ET FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)

Novartis today announced the US Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) and has granted...


Jun 04, 2019, 13:03 ET Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®

Novartis announced today results from the landmark COMBI-d and COMBI-v clinical trials, concluding that first-line treatment with Tafinlar...


Jun 03, 2019, 01:19 ET Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials

Novartis announced today new data and clinical trial updates in NSCLC at the ASCO 2019 Annual Meeting. This includes primary efficacy results from...


Jun 01, 2019, 07:35 ET Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial

Novartis today announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy1. The Phase 3...


May 24, 2019, 16:51 ET FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer

Novartis today announced the US Food and Drug Administration (FDA) has approved Piqray® (alpelisib, formerly BYL719) in combination with fulvestrant...


May 07, 2019, 13:55 ET New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1

AveXis, a Novartis company, today announced interim long-term follow-up data from the Phase 1 START trial of the investigational product Zolgensma®...


May 05, 2019, 11:30 ET AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients

AveXis, a Novartis company, today announced interim data from ongoing trials of the investigational product Zolgensma® (onasemnogene...


Mar 16, 2019, 13:15 ET Novartis late-breaking data further support initiation of Entresto in hospital and as a first-choice systolic heart failure therapy in stabilized patients

Novartis announced today new results from a 4-week extension of the landmark PIONEER-HF trial, presented as a late-breaker at the American College of ...


Jan 28, 2019, 09:00 ET Novartis data show psoriasis patients treated with Cosentyx® reported improvements in quality of life measures as early as Week 4

Novartis announced today results from a pooled analysis of four Phase 3 clinical trials demonstrating patients with moderate-to-severe plaque...


Dec 02, 2018, 10:24 ET Real-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies

Novartis announced results of a retrospective, real-world evidence study in patients with immune thrombocytopenia (ITP) treated with Promacta®...


Dec 01, 2018, 10:26 ET Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program

New data from a post hoc analysis of the Phase II SUSTAIN study of crizanlizumab -- a once-a-month, humanized anti-P-selectin monoclonal antibody...


Nov 02, 2018, 17:27 ET Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology

Novartis will present new research that may transform the way serious blood diseases and a certain type of breast cancer are treated at the upcoming...


Sep 20, 2018, 09:17 ET Novartis teams up with recording artist and actress Jordin Sparks and SCDAA to launch Generation S, an inspiring new sickle cell storytelling project

Novartis is teaming up with Grammy®-nominated singer, film and Broadway star Jordin Sparks and the Sickle Cell Disease Association of America, Inc....


Sep 12, 2018, 17:02 ET Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis

Novartis today announced that The New England Journal of Medicine (NEJM) has published full results from the landmark Phase III Gilenya® (fingolimod) ...


Jul 18, 2018, 12:59 ET Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

Novartis today announced a new approval for Kisqali® (ribociclib) from the US Food and Drug Administration (FDA) for women with hormone-receptor...


Jul 12, 2018, 07:15 ET Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community

Novartis today launched its Galaxies of Hope app, a unique digital experience created to support the neuroendocrine tumor (NET) community. Galaxies...


Jul 06, 2018, 16:15 ET Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance

Sandoz Inc. (Sandoz) and its affiliate, Novartis Pharmaceuticals Corporation (Novartis), today announced a voluntary recall and corrective action...


Jun 19, 2018, 04:02 ET Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of new evidence that Cosentyx® (secukinumab)...


Jun 15, 2018, 07:00 ET Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life

Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life,...


May 30, 2018, 07:00 ET FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)

Novartis announced today that the US Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and...


May 17, 2018, 09:35 ET Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer

Novartis will present data from across its oncology portfolio at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) ...